← Back to Clinical Trials
Recruiting NCT06891573

NCT06891573 South Korean Study to Prevent Frailty and Aging-related Diseases Through Lifestyle Intervention

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06891573
Status Recruiting
Phase
Sponsor Seong Hye Choi, MD
Condition Frailty
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2025-02-26
Primary Completion 2025-12-20

Eligibility & Interventions

Sex All sexes
Min Age 60 Years
Max Age 90 Years
Study Type INTERVENTIONAL
Interventions
Lifestyle Management

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2025-02-26 with a primary completion date of 2025-12-20.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this feasibility randomized controlled trial is to investigate the applicability of software that aims to improve symptoms of frailty by implementing customized interventions such as physical exercise and cognitive training implemented through a mobile app for 16 weeks for patients diagnosed with frailty or prefrailty. The primary outcomes are adherence, retention rates, and recruitment rates. Participants will participate in customized interventions including physical exercise, cognitive training, nutritional guidance, and management of disease related to frailty for 16 weeks.

Eligibility Criteria

Inclusion Criteria: * 60-90 years of age * Residing in the community * Total score of Modified Fried frailty phenotype score ≥ 1 point * Korean Mini-Mental State Examination-2 z-score ≥ -1.5 * Can read and write * Being able to use the a mobile app through education or having someone help a participant use the mobile app * Having a reliable informant who could provide investigators with the requested information. * written informed consent Exclusion Criteria: * Major psychiatric illness such as major depressive disorders * Dementia * Other neurodegenerative disease (e.g., Parkinson's disease) * Malignancy within five years * Cardiac stent or revascularization within one year * Serious or unstable symptomatic cardiovascular disease * Other serious or unstable medical disease such as acute or severe asthma, active gastric ulcer, severe liver disease, or severe renal disease * Severe loss of vision, hearing, or communicative disability * Significant laboratory abnormality that may result in cognitive impairment * Any conditions preventing cooperation as judged by the study physician * Unable to participate in exercise program safely * Coincident participation in any other intervention trial

Contact & Investigator

Central Contact

Seong Hye Choi, MD, PhD

✉ sseonghye@inha.ac.kr

📞 82 10-3120-2947

Principal Investigator

Seong Hye Choi, MD, PhD

PRINCIPAL INVESTIGATOR

Inha University Hospital

Frequently Asked Questions

Who can join the NCT06891573 clinical trial?

This trial is open to participants of all sexes, aged 60 Years or older, up to 90 Years, studying Frailty. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06891573 currently recruiting?

Yes, NCT06891573 is actively recruiting participants. Contact the research team at sseonghye@inha.ac.kr for enrollment information.

Where is the NCT06891573 trial being conducted?

This trial is being conducted at Incheon, South Korea, Seoul, South Korea, Suwon, South Korea.

Who is sponsoring the NCT06891573 clinical trial?

NCT06891573 is sponsored by Seong Hye Choi, MD. The principal investigator is Seong Hye Choi, MD, PhD at Inha University Hospital. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology